Erratum: Integrated molecular dissection of the epidermal growth factor receptor (EGFR) oncogenic pathway to predict response to EGFR-targeted monoclonal antibodies in metastatic colorectal cancer (Targeted Oncology DOI 10.1007/s11523-010-0138-5);Integrated molecular dissection of the epidermal growth factor receptor (EFGR) oncogenic pathway to predict response to EGFR-targeted monoclonal antibodies in metastatic colorectal cancer

Targeted Oncology

Volumn 5, Issue 1, 2010, Pages 19-28

  Sartore Bianchi, Andrea ^a   Bencardino, Katia ^a   Di Nicolantonio, Federica ^b   Pozzi, Federico ^a   Funaioli, Chiara ^a   Gambi, Valentina ^a   Arena, Sabrina ^b   Martini, Miriam ^b   Lamba, Simona ^b   Cassingena, Andrea ^a   Schiavo, Roberta ^a   Bardelli, Alberto ^b,c   Siena, Salvatore ^a  

^a OSPEDALE NIGUARDA CA GRANDA   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

^c FIRC INSTITUTE OF MOLECULAR ONCOLOGY   (Italy)

Author keywords

Biomarkers; Colorectal cancer; EGFR; Monoclonal antibodies

Indexed keywords

B RAF KINASE; BEVACIZUMAB; CAPECITABINE; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; K RAS PROTEIN; MONOCLONAL ANTIBODY; OXALIPLATIN; PANITUMUMAB; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN PIK3CA; SORAFENIB; UNCLASSIFIED DRUG; KRAS PROTEIN, HUMAN; ONCOPROTEIN; PHARMACOLOGICAL BIOMARKER; RAS PROTEIN;

CLINICAL DECISION MAKING; CLINICAL TRIAL; COLON CANCER; COLORECTAL CANCER; DRUG SENSITIVITY; DRUG TARGETING; GENE ACTIVATION; GENE DOSAGE; GENE MUTATION; HUMAN; METASTASIS; ONCOGENE K RAS; PATIENT SELECTION; PREDICTION; PRIORITY JOURNAL; PROTEIN ANALYSIS; REVIEW; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; TREATMENT RESPONSE; ANIMAL; CARCINOMA; COLORECTAL NEOPLASMS; DECISION MAKING; DRUG RESISTANCE; GENETICS; IMMUNOLOGY; METABOLISM; MUTATION; PATHOLOGY; PROGNOSIS;

ANIMALS; ANTIBODIES, MONOCLONAL; BIOMARKERS, PHARMACOLOGICAL; CARCINOMA; COLORECTAL NEOPLASMS; DECISION MAKING; DRUG RESISTANCE, NEOPLASM; GENE DOSAGE; HUMANS; MUTATION; NEOPLASM METASTASIS; PROGNOSIS; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 77952892341     PISSN: 17762596     EISSN: 1776260X     Source Type: Journal    
DOI: 10.1007/s11523-010-0142-9     Document Type: Erratum

References (52)

1. E Winer J Gralow L Diller, et al. 2008 American Society of Clinical Oncology. Clinical cancer advances 2008: major research advances in cancer treatment, prevention, and screening-a report from the American Society of Clinical Oncology J Clin Oncol 27 812 826 10.1200/JCO.2008.21.2134 19103723
2. CS Karapetis S Khambata-Ford DJ Jonker, et al. 2008 K-ras mutations and benefit from cetuximab in advanced colorectal cancer N Engl J Med 359 1757 1765 10.1056/NEJMoa0804385 1:CAS:528:DC%2BD1cXht12nu77J 18946061
3. H Linardou IJ Dahabreh D Kanaloupiti, et al. 2008 Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer Lancet Oncol 9 962 972 10.1016/S1470-2045(08)70206-7 1:CAS:528:DC%2BD1cXhtFOmurvJ 18804418
4. M Moroni S Veronese S Benvenuti, et al. 2005 Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study Lancet Oncol 6 279 286 10.1016/S1470-2045(05)70102-9 1:CAS:528:DC%2BD2MXjs1Krsb8%3D 15863375 (Pubitemid 40590264)
5. JL Bos 1989 RAS oncogenes in human cancer: a review Cancer Res 49 4682 4689 1:CAS:528:DyaL1MXltlWksL4%3D 2547513
6. Y Yarden MX Sliwkowski 2001 Untangling the ErbB signalling network Nat Rev Mol Cell Biol 2 127 137 10.1038/35052073 1:CAS:528:DC%2BD3MXivVWnt7k%3D 11252954 (Pubitemid 33674041)
7. JA McCubrey LS Steelman SL Abrams JT Lee, et al. 2006 Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance Adv Enzyme Regul 46 249 279 10.1016/j.advenzreg.2006.01.004 1:CAS:528:DC%2BD1cXhs12lurs%3D 16854453 (Pubitemid 44301348)
8. YH Tan Y Liu KW Eu, et al. 2008 Detection of B-RAF V600E mutation by pyrosequencing Pathology 40 295 298 10.1080/00313020801911512 1:CAS:528:DC%2BD1cXlt1Shsrw%3D 18428050 (Pubitemid 351563933)
9. D Calistri C Rengucci I Seymour, et al. 2005 Mutation analysis of p53, KRAS and B-RAF genes in colorectal cancer progression J Cell Physiol 204 484 488 10.1002/jcp.20310 1:CAS:528:DC%2BD2MXlvFCrsL0%3D 15702478 (Pubitemid 40934643)
10. L Barault N Veyrie V Jooste, et al. 2008 Mutations in the RAS-MAPK, PI(3)K (phosphatidylinositol-3-OH kinase) signaling network correlate with poor survival in a population-based series of colon cancers Int J Cancer 122 2255 2259 10.1002/ijc.23388 1:CAS:528:DC%2BD1cXkslynsb4%3D 18224685 (Pubitemid 351542328)
11. H Rajagopalan A Bardelli C Lengauer, et al. 2002 Tumorigenesis: RAF/RAS oncogenes and mismatchrepair status Nature 418 934 10.1038/418934a 1:CAS:528:DC%2BD38XmsFWksLs%3D 12198537 (Pubitemid 34976022)
12. F Di Nicolantonio M Martini F Molinari, et al. 2008 Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer J Clin Oncol 26 5705 5712 10.1200/JCO.2008.18.0786 19001320
13. F Loupakis A Ruzzo C Cremolini, et al. 2009 KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer Br J Cancer 18 715 721 10.1038/sj.bjc.6605177
14. Van Cutsem E, Lang Y, Folprecht G et al (2010) Cetuximab plus FOLFIRI in the treatment of metastatic colorectal cancer-the influence of KRAS and BRAF biomarkers on outcome: update data from the CRYSTAL trial. Proceedings of the 2010 Gastrointestinal Cancers Symposium. Abstract no. 281
15. J Tol ID Nagtegaal CJ Punt 2009 BRAF mutation in metastatic colorectal cancer N Engl J Med 361 98 99 10.1056/NEJMc0904160 1:CAS:528: DC%2BD1MXotFWqsbg%3D 19571295
16. J Souglakos J Philips R Wang S Marwah, et al. 2009 Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer Br J Cancer 101 465 472 10.1038/sj.bjc.6605164 1:CAS:528:DC%2BD1MXpsVKmsr4%3D 19603024
17. AD Roth S Tejpar M Delorenzi, et al. 2010 Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial J Clin Oncol 28 466 474 10.1200/JCO.2009.23.3452 1:CAS:528:DC%2BC3cXivFartb4%3D 20008640
18. HJ Andreyev AR Norman D Cunningham JR Oates PA Clarke 1998 Kirsten ras mutations in patients with colorectal cancer: the multicenter "RASCAL" study Natl Cancer Inst 90 675 684 10.1093/jnci/90.9.675 1:CAS:528: DyaK1cXjtlSiu7s%3D
19. RG Amado M Wolf M Peeters, et al. 2008 Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer J Clin Oncol 26 1626 1634 10.1200/JCO.2007.14.7116 1:CAS:528:DC%2BD1cXltlWhsrw%3D 18316791
20. Y Nagata KH Lan X Zhou, et al. 2004 PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients Cancer Cell 6 117 127 10.1016/j.ccr.2004.06.022 1:CAS:528: DC%2BD2cXns1arsr8%3D 15324695 (Pubitemid 39485684)
21. IK Mellinghoff MY Wang I Vivanco, et al. 2005 Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors N Engl J Med 353 2012 2024 10.1056/NEJMoa051918 1:CAS:528:DC%2BD2MXht1SrtrrE 16282176 (Pubitemid 41609094)
22. S Velho C Oliveira A Ferreira, et al. 2005 The prevalence of PIK3CA mutations in gastric and colon cancer Eur J Cancer 41 1649 1654 10.1016/j.ejca.2005.04.022 1:CAS:528:DC%2BD2MXmsVCmu7s%3D 15994075 (Pubitemid 40981849)
23. M Frattini P Saletti E Romagnani, et al. 2007 PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients Br J Cancer 97 1139 1145 10.1038/sj.bjc.6604009 1:CAS:528:DC%2BD2sXhtFKktb7P 17940504 (Pubitemid 47587019)
24. F Loupakis L Pollina I Stasi, et al. 2009 PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer J Clin Oncol 27 2622 2629 10.1200/JCO.2008.20.2796 1:CAS:528:DC%2BD1MXnslWit7o%3D 19398573
25. A Sartore-Bianchi F Di Nicolantonio M Nichelatti, et al. 2009 Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer PLoS One 4 e7287 10.1371/journal.pone.0007287 19806185
26. P Laurent-Puig A Cayre G Manceau, et al. 2009 Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer J Clin Oncol 27 5924 5930 10.1200/JCO.2008.21.6796 1:CAS:528:DC%2BC3cXhtVWis7c%3D 19884556
27. M Jhawer S Goel AJ Wilson, et al. 2008 PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab Cancer Res 68 1953 1961 10.1158/0008-5472.CAN-07- 5659 1:CAS:528:DC%2BD1cXjtFOhtro%3D 18339877 (Pubitemid 351416582)
28. A Lievre JB Bachet D Le Corre, et al. 2006 KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer Cancer Res 66 3992 3995 10.1158/0008-5472.CAN-06-0191 1:CAS:528:DC%2BD28XjsFSlsb0%3D 16618717
29. F Perrone A Lampis M Orsenigo, et al. 2009 PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients Ann Oncol 20 84 90 10.1093/annonc/mdn541 1:STN:280: DC%2BD1M%2Fns1yktw%3D%3D 18669866
30. A Sartore-Bianchi M Martini F Molinari, et al. 2009 PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies Cancer Res 69 1851 1857 10.1158/0008-5472.CAN-08-2466 1:CAS:528:DC%2BD1MXisFSrt7Y%3D 19223544
31. H Prenen J De Schutter B Jacobs, et al. 2009 PIK3CA mutations are not a major determinant of resistance to the epidermal growth factor receptor inhibitor cetuximab in metastatic colorectal cancer Clin Cancer Res 15 3184 3188 10.1158/1078-0432.CCR-08-2961 1:CAS:528:DC%2BD1MXltFOrur0%3D 19366826
32. S Ogino K Nosho GJ Kirkner, et al. 2009 PIK3CA mutation is associated with poor prognosis among patients with curatively resected colon cancer J Clin Oncol 27 1477 1484 10.1200/JCO.2008.18.6544 1:CAS:528:DC%2BD1MXksF2hsL4%3D 19237633
33. E Razis E Briasoulis E Vrettou, et al. 2008 Potential value of PTEN in predicting cetuximab response in colorectal cancer. An exploratory study. BMC Cancer 8 234 10.1186/1471-2407-8-234 18700047
34. L Zhao PK Vogt 2008 Helical domain and kinase domain mutations in p110alpha of phosphatidylinositol 3-kinase induce gain of function by different mechanisms Proc Natl Acad Sci U S A 105 2652 2657 10.1073/pnas.0712169105 1:CAS:528:DC%2BD1cXis1yjtr0%3D 18268322 (Pubitemid 351520568)
35. A Goel C Arnold D Niedzwiecki, et al. 2004 Frequent inactivation of PTEN by promoter hypermethylation in microsatellite instability-high sporadic colorectal cancers Cancer Res 64 3014 3021 10.1158/0008-5472.CAN-2401-2 1:CAS:528:DC%2BD2cXjs1ehsbo%3D 15126336 (Pubitemid 38581399)
36. A Bardelli S Siena 2010 Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer J Clin Oncol 28 7 1254 1261 10.1200/JCO.2009.24.6116 1:CAS:528:DC%2BC3cXktF2ltbk%3D 20100961
37. A Ooi T Takehana X Li, et al. 2004 Protein overexpression and gene amplification of HER-2 and EGFR in colorectal cancers: an immunohistochemical and fluorescent in situ hybridization study Mod Pathol 17 895 904 10.1038/modpathol.3800137 1:CAS:528:DC%2BD2cXmvVOltrk%3D 15143334 (Pubitemid 38993773)
38. J Shia DS Klimstra AR Li, et al. 2005 Epidermal growth factor receptor expression and gene amplification in colorectal carcinoma: an immunohistochemical and chromogenic in situ hybridization study Mod Pathol 18 1350 1356 10.1038/modpathol.3800417 1:CAS:528:DC%2BD2MXhtVWiu7bP 15832190 (Pubitemid 41348654)
39. HJ Lenz E Van Cutsem S Khambata-Ford, et al. 2006 Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines J Clin Oncol 24 4914 4921 10.1200/JCO.2006.06.7595 1:CAS:528:DC%2BD28Xht1eiu73K 17050875 (Pubitemid 46630920)
40. D Vallböhmer W Zhang M Gordon, et al. 2005 Molecular determinants of cetuximab efficacy J Clin Oncol 23 3536 3544 10.1200/JCO.2005.09.100 15908664
41. A Sartore-Bianchi M Moroni S Veronese, et al. 2007 Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab J Clin Oncol 25 3238 3245 10.1200/JCO.2007.11. 5956 1:CAS:528:DC%2BD2sXhtVWqs7vN 17664472 (Pubitemid 47325607)
42. M Scartozzi I Bearzi A Mandolesi, et al. 2009 Epidermal growth factor receptor (EGFR) gene copy number (GCN) correlates with clinical activity of irinotecan-cetuximab in K-RAS wild-type colorectal cancer: a fluorescence in situ (FISH) and chromogenic in situ hybridization (CISH) analysis BMC Cancer 9 303 10.1186/1471-2407-9-303 19712476
43. FR Hirsch RS Herbst C Olsen, et al. 2008 Increased EGFR gene copy number detected by fluorescent in situ hybridization predicts outcome in non-small-cell lung cancer patients treated with cetuximab and chemotherapy J Clin Oncol 26 3351 3357 10.1200/JCO.2007.14.0111 1:CAS:528:DC%2BD1cXpvVWitrw%3D 18612151
44. N Personeni S Fieuws H Piessevaux, et al. 2008 Clinical usefulness of EGFR gene copy number as a predictive marker in colorectal cancer patients treated with cetuximab: a fluorescent in situ hybridization study Clin Cancer Res 14 5869 5876 10.1158/1078-0432.CCR-08-0449 1:CAS:528:DC%2BD1cXhtFaitrjP 18794099
45. F Cappuzzo G Finocchiaro E Rossi, et al. 2008 EGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patients Ann Oncol 19 717 723 10.1093/annonc/mdm492 1:STN:280:DC%2BD1c3gsVKgsA%3D%3D 17974556 (Pubitemid 351461042)
46. S Benvenuti A Sartore-Bianchi F Di Nicolantonio, et al. 2007 Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies Cancer Res 67 2643 2648 10.1158/0008-5472.CAN-06-4158 1:CAS:528: DC%2BD2sXivV2ns7w%3D 17363584 (Pubitemid 46548951)
47. W De Roock B Claes G Fountzilas, et al. 2009 PIK3CA, BRAF and KRAS mutations and outcome prediction in chemorefractory metastatic colorectal cancer (mCRC) patients treated with EGFR targeting monoclonal antibodies (MoAbs): Results of a European Consortium Eur J Cancer 7 302s (abstract 6005)
48. F Di Fiore F Blanchard F Charbonnier F Le Pessot A Lamy MP Galais L Bastit A Killian R Sesboüé JJ Tuech AM Queuniet B Paillot JC Sabourin F Michot P Michel T Frebourg 2007 Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy Br J Cancer 96 8 1166 1169 10.1038/sj.bjc.6603685 17375050 (Pubitemid 46625066)
49. S Khambata-Ford CR Garrett NJ Meropol M Basik CT Harbison S Wu TW Wong X Huang CH Takimoto AK Godwin BR Tan SS Krishnamurthi HA Burris 3rd EA Poplin M Hidalgo J Baselga EA Clark DJ Mauro 2007 Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab J Clin Oncol 25 22 3230 3237 10.1200/JCO.2006.10.5437 1:CAS:528:DC%2BD2sXhtVWqs7rF 17664471 (Pubitemid 47325606)
50. C Bokemeyer I Bondarenko A Makhson JT Hartmann J Aparicio F de Braud S Donea H Ludwig G Schuch C Stroh AH Loos A Zubel P Koralewski 2009 Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer J Clin Oncol 27 5 663 671 10.1200/JCO.2008.20.8397 1:CAS:528:DC%2BD1MXjsVCjsrk%3D 19114683
51. E Van Cutsem CH Köhne E Hitre J Zaluski CR Chang Chien A Makhson G D'Haens T Pintér R Lim G Bodoky JK Roh G Folprecht P Ruff C Stroh S Tejpar M Schlichting J Nippgen P Rougier 2009 Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer N Engl J Med 360 14 1408 1417 10.1056/NEJMoa0805019 19339720
52. B Jacobs W De Roock H Piessevaux R Van Oirbeek B Biesmans J De Schutter S Fieuws J Vandesompele M Peeters JL Van Laethem Y Humblet F Pénault- Llorca G De Hertogh P Laurent-Puig E Van Cutsem S Tejpar 2009 Amphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab J Clin Oncol 27 30 5068 5074 10.1200/JCO.2008.21.3744 1:CAS:528:DC%2BD1MXhsVCrsrrO 19738126